WO2022055094A1 - L-글루탐산 생산 재조합 미생물 및 이를 이용한 l-글루탐산의 제조방법 - Google Patents
L-글루탐산 생산 재조합 미생물 및 이를 이용한 l-글루탐산의 제조방법 Download PDFInfo
- Publication number
- WO2022055094A1 WO2022055094A1 PCT/KR2021/008262 KR2021008262W WO2022055094A1 WO 2022055094 A1 WO2022055094 A1 WO 2022055094A1 KR 2021008262 W KR2021008262 W KR 2021008262W WO 2022055094 A1 WO2022055094 A1 WO 2022055094A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- glutamic acid
- sequence
- polypeptide
- sbta
- Prior art date
Links
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 title claims abstract description 133
- 244000005700 microbiome Species 0.000 title claims abstract description 96
- 229960002989 glutamic acid Drugs 0.000 title claims abstract description 68
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 28
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 149
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 101
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 101
- 239000002157 polynucleotide Substances 0.000 claims abstract description 101
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 89
- 150000001413 amino acids Chemical group 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 38
- 241000186226 Corynebacterium glutamicum Species 0.000 claims description 29
- 241000186216 Corynebacterium Species 0.000 claims description 24
- 238000012258 culturing Methods 0.000 claims description 11
- 241000192700 Cyanobacteria Species 0.000 claims description 7
- 230000002238 attenuated effect Effects 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 description 87
- 102000004196 processed proteins & peptides Human genes 0.000 description 87
- 108090000765 processed proteins & peptides Proteins 0.000 description 87
- 235000018102 proteins Nutrition 0.000 description 73
- 230000000694 effects Effects 0.000 description 66
- 239000013598 vector Substances 0.000 description 34
- 230000014509 gene expression Effects 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 28
- 239000002773 nucleotide Substances 0.000 description 28
- 125000003729 nucleotide group Chemical group 0.000 description 28
- 239000002609 medium Substances 0.000 description 22
- 238000012986 modification Methods 0.000 description 21
- 230000004048 modification Effects 0.000 description 21
- 210000000349 chromosome Anatomy 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 14
- 238000006467 substitution reaction Methods 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 13
- 230000009466 transformation Effects 0.000 description 12
- 238000010367 cloning Methods 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 108020004705 Codon Proteins 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- 238000004925 denaturation Methods 0.000 description 10
- 230000036425 denaturation Effects 0.000 description 10
- 101150021317 odhA gene Proteins 0.000 description 10
- 238000006116 polymerization reaction Methods 0.000 description 10
- 238000013519 translation Methods 0.000 description 10
- 238000007792 addition Methods 0.000 description 9
- 238000012217 deletion Methods 0.000 description 9
- 230000037430 deletion Effects 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 238000003780 insertion Methods 0.000 description 9
- 230000037431 insertion Effects 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 108091081024 Start codon Proteins 0.000 description 8
- 230000001747 exhibiting effect Effects 0.000 description 8
- 230000006801 homologous recombination Effects 0.000 description 8
- 238000002744 homologous recombination Methods 0.000 description 8
- 238000011144 upstream manufacturing Methods 0.000 description 8
- 101000713310 Homo sapiens Sodium bicarbonate cotransporter 3 Proteins 0.000 description 7
- 102100036911 Sodium bicarbonate cotransporter 3 Human genes 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000002759 chromosomal effect Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000004952 protein activity Effects 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 101150111745 sucA gene Proteins 0.000 description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 241000192584 Synechocystis Species 0.000 description 5
- 238000000137 annealing Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 108020003589 5' Untranslated Regions Proteins 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 238000012268 genome sequencing Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 235000013379 molasses Nutrition 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000013587 production medium Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108020005544 Antisense RNA Proteins 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 241000446654 Corynebacterium deserti Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003184 complementary RNA Substances 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 229910000358 iron sulfate Inorganic materials 0.000 description 3
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000186145 Corynebacterium ammoniagenes Species 0.000 description 2
- 241001134763 Corynebacterium flavescens Species 0.000 description 2
- 241000291063 Corynebacterium halotolerans Species 0.000 description 2
- 241000024402 Corynebacterium imitans Species 0.000 description 2
- 241000128247 Corynebacterium pollutisoli Species 0.000 description 2
- 241000158523 Corynebacterium striatum Species 0.000 description 2
- 241000960580 Corynebacterium testudinoris Species 0.000 description 2
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 2
- 241000588698 Erwinia Species 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 101100364971 Mus musculus Scai gene Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 101100309436 Streptococcus mutans serotype c (strain ATCC 700610 / UA159) ftf gene Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000192581 Synechocystis sp. Species 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000006652 catabolic pathway Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000012224 gene deletion Methods 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 101150025220 sacB gene Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 229960000344 thiamine hydrochloride Drugs 0.000 description 2
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 2
- 239000011747 thiamine hydrochloride Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000011426 transformation method Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 101100533902 Arabidopsis thaliana SPL13A gene Proteins 0.000 description 1
- 101100533904 Arabidopsis thaliana SPL13B gene Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 101100455080 Bacillus subtilis (strain 168) lmrB gene Proteins 0.000 description 1
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000186248 Corynebacterium callunae Species 0.000 description 1
- 241001605246 Corynebacterium crudilactis Species 0.000 description 1
- 241001644925 Corynebacterium efficiens Species 0.000 description 1
- 241000334675 Corynebacterium singulare Species 0.000 description 1
- 241000186249 Corynebacterium sp. Species 0.000 description 1
- 241000186308 Corynebacterium stationis Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101100070556 Oryza sativa subsp. japonica HSFA4D gene Proteins 0.000 description 1
- 101100043227 Oryza sativa subsp. japonica SPL13 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000520272 Pantoea Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 101150099282 SPL7 gene Proteins 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000192593 Synechocystis sp. PCC 6803 Species 0.000 description 1
- 102000008579 Transposases Human genes 0.000 description 1
- 108010020764 Transposases Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 101150019505 bicA gene Proteins 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- UJKDYMOBUGTJLZ-RUCXOUQFSA-N ksc605q1h Chemical compound OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CCC(O)=O UJKDYMOBUGTJLZ-RUCXOUQFSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920001522 polyglycol ester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000013077 target material Substances 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 101150062776 yccA gene Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/14—Glutamic acid; Glutamine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/15—Corynebacterium
Definitions
- the present application relates to an L-glutamic acid-producing microorganism comprising SbtA protein or a polynucleotide encoding SbtA protein, and a method for producing L-glutamic acid using the same.
- L-glutamic acid is a representative amino acid produced by fermentation, and has a unique taste, so it is one of the important amino acids widely used in the food field as well as in the pharmaceutical field and other animal feed fields.
- L-glutamic acid is Corynebacterium ( Corynebacterium ) Genus, Escherichia coli , Bacillus subtilis ( Bacillus ), actinomycetes ( Streptomyces ), Penicillum genus, Klebsiella , Erwinia ( Erwinia ), or Pantoea , such as microorganisms of the genus
- a method for producing using is known (US Pat. No. 3,220,929, US Pat. No. 6,682,912).
- the present inventors have developed a microorganism of the genus Corynebacterium that produces L-glutamic acid at a high concentration by introducing a foreign protein, thereby completing the present application.
- One object of the present application is to provide a recombinant microorganism of the genus of Corynebacterium for producing L-glutamic acid, including a polynucleotide encoding SbtA protein or SbtA protein. .
- Another object of the present application is to provide a method for producing L-glutamic acid, comprising culturing in a medium a recombinant microorganism of the genus Corynebacterium that produces L-glutamic acid comprising a polynucleotide encoding SbtA protein or SbtA protein will be.
- the recombinant microorganism of the genus Corynebacterium producing L-glutamic acid comprising the SbtA protein or the polynucleotide encoding the SbtA protein of the present application can produce L-glutamic acid in high yield, so that it can be usefully used for industrial production of L-glutamic acid. there is.
- FIG. 1 is a schematic diagram of a pDCM2 plasmid.
- One aspect of the present application for achieving the object of the present application is to provide a recombinant microorganism of the genus Corynebacterium for producing L-glutamic acid, including SbtA protein or a polynucleotide encoding the SbtA protein.
- SbtA protein is one of the bicarbonate transporters, which promotes membrane impermeable bicarbonate, HCO 3 - , through the membrane to accelerate the treatment of carbon dioxide (CO 2 ) and contributes to carbon dioxide It is one of the proteins expressed for the capture and efficient use of Bicarbonate transporters include SbtA protein and BicA protein, which transport bicarbonate into the cell, resulting in the accumulation of bicarbonate in the cell.
- the SbtA protein may be a protein derived from a microorganism different from the microorganism of the present application, or may be different from a protein inherently present in the microorganism of the present application.
- the SbtA protein may be a cyanobacteria-derived protein, but is not limited thereto.
- the SbtA protein may be a protein derived from a microorganism of the genus of Synechocystis , and more specifically, PCC 6803 of the genus of Synechocystis (Synechocystis sp. PCC 6803) or PCC 6714 of the genus of Synechocystis (Synechocystis).
- sp. PCC 6714 may be a microorganism-derived protein.
- the SbtA protein of the present application may include an amino acid sequence having 90% or more identity to the amino acid sequence of SEQ ID NO: 1.
- the amino acid sequence of SEQ ID NO: 1 can be obtained from a known database, National Institutes of Health (NIH GenBank).
- amino acid sequence having 90% or more identity with SEQ ID NO: 1 of the present application is 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 96.26% or more, 97% or more, 97.5% or more, 97.7% or more, 97.8% or more, 98% or more, 98.5% or more, 98.7% or more, 98.8% or more, 99% or more, 99.5% or more, 99.7% or more, 99.8% It may be an amino acid sequence with more or more, and less than 100% homology or identity.
- amino acid sequence having 90% or more and less than 100% homology or identity to the amino acid sequence of SEQ ID NO: 1 may be the amino acid sequence of SEQ ID NO: 30.
- amino acid sequence having such homology or identity and exhibiting the same or corresponding activity to the SbtA protein, or a bicarbonate transporter activity some sequence is deleted, modified, substituted, conservatively substituted or has an added amino acid sequence It is apparent that proteins are also included within the scope of the SbtA protein of the present application.
- the SbtA protein of the present application may have an amino acid sequence having 90% or more identity to the amino acid sequence of SEQ ID NO: 1.
- the SbtA protein of the present application may have an amino acid sequence having 90% or more identity to the amino acid sequence of SEQ ID NO: 1, consist of, or consist essentially of the amino acid sequence.
- the SbtA protein of the present application contains nonsensical additions of sequences before and after the amino acid sequence of SEQ ID NO: 1 (i.e., addition of sequences that do not alter the function of the protein at the N-terminus and/or C-terminus of the amino acid sequence) or naturally occurring mutations, It does not exclude cases having a latent mutation or conservative substitution thereof.
- the "conservative substitution” means substituting one amino acid with another amino acid having similar structural and/or chemical properties. Such amino acid substitutions may generally occur based on similarity in the polarity, charge, solubility, hydrophobicity, hydrophilicity and/or amphipathic nature of the residues. Typically, conservative substitutions may have little or no effect on the activity of the protein or polypeptide.
- the polynucleotide encoding the SbtA protein may be an sbtA gene.
- the polynucleotide encoding the SbtA protein may be derived from cyanobacteria.
- the polynucleotide encoding the SbtA protein of the present application may include a nucleotide sequence encoding an amino acid sequence having 90% or more identity to the amino acid sequence of SEQ ID NO: 1.
- the polynucleotide encoding the SbtA protein of the present application has a nucleotide sequence of SEQ ID NO: 2, a nucleotide sequence of SEQ ID NO: 31, or 90% or more identity with the amino acid sequence of SEQ ID NO: 1 or more. It may include a nucleotide sequence encoding an amino acid sequence having, but is not limited thereto.
- the polynucleotide comprising a nucleotide sequence encoding an amino acid sequence having 90% or more identity to the amino acid sequence of SEQ ID NO: 1 is a polynucleotide having a nucleotide sequence encoding an amino acid sequence having 90% or more identity to the amino acid sequence of SEQ ID NO: 1 It may be a polynucleotide consisting of or consisting essentially of a nucleotide sequence encoding an amino acid sequence having at least 90% identity with the amino acid sequence of SEQ ID NO: 1.
- polynucleotide refers to a DNA strand of a certain length or more as a polymer of nucleotides in which nucleotide monomers are connected in a long chain shape by covalent bonds.
- the polynucleotide of the present application has a nucleotide sequence of SEQ ID NO: 2, a nucleotide sequence of SEQ ID NO: 3, a nucleotide sequence of SEQ ID NO: 31, or 90% or more identity with the amino acid sequence of SEQ ID NO: 1 while having at least 90% identity
- a nucleotide sequence encoding an amino acid sequence it is obvious that a part of the nucleotide sequence is included within the scope of the present application even if it includes a polynucleotide with deletion, modification, substitution, conservative substitution or addition.
- the term "conservative substitution” means substituting one base with another base having similar structural and/or chemical properties.
- the polynucleotide of the present application various modifications may be made to the coding region within a range that does not change the polynucleotide sequence due to codon degeneracy or in consideration of codons preferred in the organism in which the polynucleotide is to be expressed.
- the polynucleotide of the present application may be a polynucleotide including the nucleotide sequence of SEQ ID NO: 2.
- polynucleotide of the present application is a probe that can be prepared from a known sbtA gene sequence, for example, hybridized with a sequence complementary to all or part of the nucleotide sequence under stringent conditions to be introduced naturally into the microorganism.
- Any polynucleotide sequence capable of increasing L-glutamic acid production ability while not a sequence present as a sequence may be included without limitation.
- the polynucleotide of the present application may be a probe that can be prepared from a known gene sequence, for example, a sequence capable of hybridizing under stringent conditions with a sequence complementary to all or part of the polynucleotide sequence of the present application, without limitation. may be included.
- the "stringent condition” means a condition that enables specific hybridization between polynucleotides. These conditions are described in J. Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press, Cold Spring Harbor, New York, 1989; FM Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York, 9.50-9.51, 11.7-11.8).
- polynucleotides with high homology or identity 70% or more, 75% or more, 76% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or a condition in which polynucleotides having 99% or more homology or identity hybridize with each other and polynucleotides with lower homology or identity do not hybridize, or 60 ° C., which is a washing condition of conventional Southern hybridization; 1 ⁇ SSC, 0.1% SDS, specifically at a salt concentration and temperature equivalent to 60° C., 0.1 ⁇ SSC, 0.1% SDS, more specifically 68° C., 0.1 ⁇ SSC, 0.1% SDS, washed once, specifically 2 to 3 times conditions can be enumerated.
- Hybridization requires that two nucleic acids have complementary sequences, although mismatch between bases is possible depending on the stringency of hybridization.
- complementary is used to describe the relationship between nucleotide bases capable of hybridizing to each other.
- adenine is complementary to thymine
- cytosine is complementary to guanine.
- the polynucleotides of the present application may also include substantially similar nucleic acid sequences as well as isolated nucleic acid fragments complementary to the overall sequence.
- a polynucleotide having homology or identity with the polynucleotide of the present application can be detected using the hybridization conditions including a hybridization step at a Tm value of 55° C. and using the above-described conditions.
- the Tm value may be 60°C, 63°C, or 65°C, but is not limited thereto and may be appropriately adjusted by those skilled in the art depending on the purpose.
- the appropriate stringency for hybridizing the polynucleotides depends on the length of the polynucleotides and the degree of complementarity, and the parameters are well known in the art (eg, J. Sambrook et al., supra).
- the term 'homology' or 'identity' refers to the degree of similarity between two given amino acid sequences or nucleotide sequences and may be expressed as a percentage.
- the terms homology and identity can often be used interchangeably.
- Sequence homology or identity of a conserved polynucleotide or polypeptide is determined by standard alignment algorithms, with default gap penalties established by the program used may be used. Substantially homologous or identical sequences are generally capable of hybridizing with all or part of a sequence under moderate or high stringent conditions. It is apparent that hybridization also includes hybridization with a polynucleotide containing a common codon in a polynucleotide or a codon in consideration of codon degeneracy.
- a GAP program can be defined as the total number of symbols in the shorter of two sequences divided by the number of similarly aligned symbols (ie, nucleotides or amino acids).
- Default parameters for the GAP program are: (1) a binary comparison matrix (containing values of 1 for identity and 0 for non-identity) and Schwartz and Dayhoff, eds., Atlas Of Protein Sequence And Structure, National Biomedical Research Foundation , pp. 353-358 (1979), Gribskov et al (1986) Nucl. Acids Res. 14: weighted comparison matrix of 6745 (or EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap (or a gap opening penalty of 10, a gap extension penalty of 0.5); and (3) no penalty for end gaps.
- the SbtA protein contained in the recombinant microorganism of the present application may be expressed in the microorganism of the genus Corynebacterium by a conventional method known in the art.
- expression used for a protein in the present application refers to a state in which a target protein is introduced into a microorganism or modified to be expressed in the microorganism.
- the “protein of interest” may be the aforementioned SbtA protein.
- introduction used for a protein in the present application means that the activity of the protein is introduced into a microorganism without a specific protein activity. This can also be expressed as enhancement of protein activity in microorganisms without specific protein activity.
- Introduction of the protein may be performed by introducing a foreign polynucleotide encoding a protein exhibiting the same/similar activity as the protein, or a codon-optimized mutant polynucleotide thereof into a host cell.
- the foreign polynucleotide may be used without limitation in origin or sequence as long as it exhibits the same/similar activity as the protein.
- the introduced foreign polynucleotide can be introduced into the host cell by optimizing its codon so that the optimized transcription and translation are performed in the host cell.
- the introduction can be performed by appropriately selecting a known transformation method by those skilled in the art, and the introduced polynucleotide is expressed in a host cell to generate a protein and enhance its activity.
- the term “enhancement” of a polypeptide activity means that the activity of the polypeptide is increased compared to the intrinsic activity.
- the reinforcement may be used interchangeably with terms such as activation, up-regulation, overexpression, and increase.
- activation, enhancement, upregulation, overexpression, and increase may include all of those exhibiting an activity that was not originally possessed, or exhibiting an improved activity compared to intrinsic activity or activity before modification.
- intrinsic activity refers to the activity of a specific polypeptide originally possessed by the parent strain or unmodified microorganism before transformation when the trait is changed due to genetic mutation caused by natural or artificial factors.
- the enrichment can be achieved by introducing an exogenous polypeptide, or by enhancing the activity and/or concentration (expression amount) of an endogenous polypeptide. Whether or not the activity of the polypeptide is enhanced can be confirmed from the increase in the level of activity, expression level, or the amount of product excreted from the polypeptide.
- the enhancement of the activity of the polypeptide can be applied by various methods well known in the art, and is not limited as long as it can enhance the activity of the target polypeptide compared to the microorganism before modification. Specifically, it may be one using genetic engineering and/or protein engineering well known to those skilled in the art, which is a routine method of molecular biology, but is not limited thereto (eg, Sitnicka et al. Functional Analysis of Genes. Advances in Cell). Biology 2010, Vol. 2. 1-16, Sambrook et al. Molecular Cloning 2012, etc.).
- modification of the polynucleotide sequence encoding the polypeptide to enhance the polypeptide activity eg, modification of the polynucleotide sequence of the polypeptide gene to encode a polypeptide modified to enhance the activity of the polypeptide
- the increase in the intracellular copy number of the polynucleotide encoding the polypeptide is achieved by introduction of a vector, to which the polynucleotide encoding the polypeptide is operably linked, which can replicate and function independently of the host, into a host cell.
- a vector to which the polynucleotide encoding the polypeptide is operably linked, which can replicate and function independently of the host, into a host cell.
- the polynucleotide encoding the polypeptide may be achieved by introducing one copy or two or more copies into a chromosome in a host cell.
- the introduction into the chromosome may be performed by introducing a vector capable of inserting the polynucleotide into the chromosome in the host cell into the host cell, but is not limited thereto.
- Replacing the gene expression control region (or expression control sequence) on the chromosome encoding the polypeptide with a sequence with strong activity is, for example, deletion, insertion, non-conservative or Conservative substitution or a combination thereof may result in a mutation in the sequence, or replacement with a sequence having a stronger activity.
- the expression control region is not particularly limited thereto, but may include a promoter, an operator sequence, a sequence encoding a ribosome binding site, and a sequence for regulating the termination of transcription and translation. As an example, it may be to replace the original promoter with a strong promoter, but is not limited thereto.
- Examples of known strong promoters include CJ1 to CJ7 promoter (US 7662943 B2), lac promoter, trp promoter, trc promoter, tac promoter, lambda phage PR promoter, PL promoter, tet promoter, gapA promoter, SPL7 promoter, SPL13 (sm3) promoter (US Patent US 10584338 B2), O2 promoter (US Patent US 10273491 B2), tkt promoter, yccA promoter, etc., but is not limited thereto.
- the modification of the nucleotide sequence encoding the start codon or 5'-UTR region of the gene transcript encoding the polypeptide is, for example, a nucleotide sequence encoding another start codon having a higher expression rate of the polypeptide compared to the intrinsic start codon. It may be a substitution, but is not limited thereto.
- the modification of the amino acid sequence or polynucleotide sequence of 4) and 5) above may include deletion, insertion, non-conservative or conservative substitution of the amino acid sequence of the polypeptide or the polynucleotide sequence encoding the polypeptide to enhance activity of the polypeptide; A combination thereof may result in sequence mutation, or replacement with an amino acid sequence or polynucleotide sequence improved to have stronger activity or an amino acid sequence or polynucleotide sequence improved to increase activity, but is not limited thereto.
- the replacement may be specifically performed by inserting a polynucleotide into a chromosome by homologous recombination, but is not limited thereto.
- the vector used may further include a selection marker for confirming whether or not the chromosome is inserted. The selection marker is the same as described above.
- the introduction of the foreign polynucleotide exhibiting the activity of the polypeptide may be introduction of the foreign polynucleotide encoding the polypeptide exhibiting the same/similar activity as the polypeptide into a host cell.
- the foreign polynucleotide is not limited in origin or sequence as long as it exhibits the same/similar activity as the polypeptide.
- the method used for the introduction can be performed by appropriately selecting a known transformation method by those skilled in the art, and the introduced polynucleotide is expressed in a host cell to generate a polypeptide and increase its activity.
- Codon optimization of the polynucleotide encoding the polypeptide is codon-optimized so that the transcription or translation of the endogenous polynucleotide is increased in the host cell, or the transcription and translation of the foreign polynucleotide is optimized in the host cell. It may be that its codons are optimized so that the
- Selecting an exposed site by analyzing the tertiary structure of the polypeptide and modifying or chemically modifying it for example, compares the sequence information of the polypeptide to be analyzed with a database in which sequence information of known proteins is stored to determine the degree of sequence similarity. Accordingly, it may be to determine a template protein candidate, check the structure based on this, and select an exposed site to be modified or chemically modified and modified or modified.
- Such enhancement of polypeptide activity is to increase the activity or concentration of the corresponding polypeptide relative to the activity or concentration of the polypeptide expressed in the wild-type or pre-modified microbial strain, or increase the amount of product produced from the polypeptide.
- the present invention is not limited thereto.
- Modification of some or all of the polynucleotide in the microorganism of the present application is (a) homologous recombination using a vector for chromosome insertion in the microorganism or genome correction using engineered nuclease (eg, CRISPR-Cas9) and/or (b) It may be induced by light and/or chemical treatments such as, but not limited to, ultraviolet and radiation.
- the method for modifying part or all of the gene may include a method by DNA recombination technology.
- a part or all of the gene may be deleted.
- the injected nucleotide sequence or vector may include a dominant selection marker, but is not limited thereto.
- the term “vector” refers to a DNA preparation containing a target polynucleotide sequence operably linked to a suitable regulatory sequence so that a target gene can be introduced in a suitable host.
- the regulatory sequences may include a promoter capable of initiating transcription, an optional operator sequence for regulating such transcription, a sequence encoding a suitable mRNA ribosome binding site, and a sequence regulating the termination of transcription and translation.
- the vector can replicate or function independently of the host genome, and can be integrated into the genome itself.
- a target polynucleotide in a chromosome may be replaced with a mutated polynucleotide through a vector for intracellular chromosome insertion. Insertion of the polynucleotide into a chromosome may be performed by any method known in the art, for example, homologous recombination, but is not limited thereto.
- the vector of the present application is not particularly limited, and any vector known in the art may be used.
- Examples of commonly used vectors include natural or recombinant plasmids, cosmids, viruses and bacteriophages.
- pWE15, M13, MBL3, MBL4, IXII, ASHII, APII, t10, t11, Charon4A, and Charon21A may be used as a phage vector or a cosmid vector
- pBR-based, pUC-based, pBluescriptII-based plasmid vectors may be used as plasmid vectors.
- pGEM-based, pTZ-based, pCL-based and pET-based and the like can be used.
- pDZ pACYC177, pACYC184, pCL, pECCG117, pUC19, pBR322, pMW118, pCC1BAC vectors and the like
- the vector used in the present application may be pDCM2 (FIG. 1, SEQ ID NO: 32) produced for insertion and replacement of genes in the Corynebacterium chromosome, but is not particularly limited thereto, and a known expression vector may be used.
- pDCM2 FIG. 1, SEQ ID NO: 32
- the term “transformation” refers to introducing a vector including a polynucleotide encoding a target protein into a host cell so that the protein encoded by the polynucleotide can be expressed in the host cell.
- the transformed polynucleotide may include all of them regardless of whether they are inserted into the chromosome of the host cell or located extrachromosomally, as long as they can be expressed in the host cell.
- the polynucleotide includes DNA and RNA encoding a target protein. The polynucleotide may be introduced into a host cell and expressed in any form, as long as it can be expressed.
- the polynucleotide may be introduced into a host cell in the form of an expression cassette, which is a gene construct including all elements necessary for self-expression.
- the expression cassette may include a promoter operably linked to the polynucleotide, a transcription termination signal, a ribosome binding site, and a translation termination signal.
- the expression cassette may be in the form of an expression vector capable of self-replication.
- the polynucleotide may be introduced into a host cell in its own form and operably linked to a sequence required for expression in the host cell, but is not limited thereto.
- operably linked in the present application means that the gene sequence is functionally linked to a promoter sequence that initiates and mediates transcription of a polynucleotide encoding a target protein of the present application.
- the method for transforming the vector of the present application includes any method of introducing a nucleic acid into a cell, and may be performed by selecting a suitable standard technique as known in the art depending on the host cell. For example, electroporation, calcium phosphate (CaPO 4 ) precipitation, calcium chloride (CaCl 2 ) precipitation, microinjection, polyethylene glycol (PEG) method, DEAE-dextran method, cationic liposome method, and Lithium acetate-DMSO method and the like, but is not limited thereto.
- recombinant microorganism in the present application includes all microorganisms in which genetic modification has occurred artificially, and a specific mechanism is As a weakened or fortified microorganism, it may be a microorganism comprising genetic modification for the production of a desired protein or product.
- the recombinant microorganism of the present application may include a microorganism genetically modified through any one or more of SbtA protein or a polynucleotide encoding the SbtA protein, and a vector including the polynucleotide; a microorganism modified to express the protein, or a polynucleotide encoding the same; a recombinant microorganism expressing the protein or a polynucleotide encoding the same; Or it may be a recombinant microorganism having the protein activity, but is not limited thereto.
- the recombinant microorganism of the present application may be a microorganism in which the activity of a part of the protein in the L-glutamic acid biosynthesis pathway is further enhanced, or the activity of a part of the protein in the L-glutamic acid degradation pathway is further weakened, so that the L-glutamic acid production ability is enhanced.
- the microorganism of the present application may be a microorganism in which the OdhA protein is further weakened. More specifically, the microorganism of the present application may be a microorganism in which the odhA gene is deleted.
- the sequence of the OdhA protein can be obtained from GenBank of NCBI, which is a known database, for example, GenBank Accession No. It may be WP_060564343.1, but is not limited thereto, and may include, without limitation, those exhibiting the same activity.
- OdhA protein weakening or odhA gene deletion is one example and not limited thereto, and the microorganism of the present application may be a microorganism in which the protein activity of various known L-glutamic acid biosynthetic pathways is enhanced or the protein activity of the degradation pathway is weakened. there is.
- the recombinant microorganism of the present application may be a microorganism treated with a compound to enable the production of L-glutamic acid as a parent strain, and specifically, the compound is N-methyl-N'-nitro-N-nitrosoguanidine (N-Methyl-N'-nitro-N-nitrosoguanidine, NTG), but is not limited thereto.
- the recombinant microorganism of the present application refers to a microorganism having an improved L-glutamic acid production ability than the parent strain or unmodified microorganism before transformation.
- the 'unmodified microorganism' does not exclude strains containing mutations that can occur naturally in microorganisms, and the expression level of genes involved in the L-glutamic acid biosynthetic pathway is regulated, either the native microorganism itself, the wild type microorganism itself, or the L-glutamic acid biosynthesis pathway. It may be a microorganism before it becomes a microorganism, or it may be a microorganism before the sbtA gene, which does not exist intrinsically, is introduced.
- the parent strain is wild-type Corynebacterium glutamicum ATCC13869, Corynebacterium glutamicum ATCC13869 in which OdhA is weakened Corynebacterium glutamicum, the Corynebacterium glutamicum ATCC13869 Corynebacterium glutamic acid obtained by treating a mutagenic agent such as N-methyl-N ⁇ -nitro-N-nitrosoguanidine (NTG) to a strain lacking odhA or Corynebacterium glutamicum KFCC 10656 strain It may be Kum BL2 (Accession No. KFCC-11074, Korean Patent No. 10-0292299), but is not limited thereto.
- the term "weakening" of a polypeptide is a concept that includes both reduced or no activity compared to intrinsic activity.
- the attenuation may be used interchangeably with terms such as inactivation, deficiency, down-regulation, decrease, reduce, attenuation, and the like.
- the attenuation is when the activity of the polypeptide itself is reduced or eliminated compared to the activity of the polypeptide possessed by the original microorganism due to mutation of the polynucleotide encoding the polypeptide, etc., inhibiting the expression of the gene encoding the polynucleotide or translation into a polypeptide
- the overall polypeptide activity level and/or concentration (expression amount) in the cell is lower than that of the native strain due to (translation) inhibition, etc., when the expression of the polynucleotide is not made at all, and/or when the expression of the polynucleotide is Even if there is no activity of the polypeptide, it may also be included.
- the "intrinsic activity” refers to the activity of a specific polypeptide originally possessed by the parent strain, wild-type or unmodified microorganism before transformation when the trait is changed due to genetic mutation caused by natural or artificial factors. This may be used interchangeably with “activity before modification”.
- activity of a polypeptide is "weakened, inactivated, deficient, reduced, downregulated, lowered, attenuated” compared to the intrinsic activity, it means that the activity of the specific polypeptide originally possessed by the parent strain or unmodified microorganism before transformation is lowered. do.
- Attenuation of the activity of the polypeptide may be performed by any method known in the art, but is not limited thereto, and may be achieved by application of various methods well known in the art (eg, Nakashima N et al., Bacterial cellular engineering by genome editing and gene silencing. Int J Mol Sci. 2014;15(2):2773-2793, Sambrook et al. Molecular Cloning 2012, etc.).
- the attenuation of the polypeptide of the present application is
- an antisense oligonucleotide eg, antisense RNA
- an antisense oligonucleotide that complementarily binds to the transcript of said gene encoding the polypeptide
- deletion of a part or all of the gene encoding the polypeptide may be the removal of the entire polynucleotide encoding the endogenous target polypeptide in the chromosome, replacement with a polynucleotide in which some nucleotides are deleted, or replacement with a marker gene.
- the above 2) modification of the expression control region is deletion, insertion, non-conservative or conservative substitution or a combination thereof, resulting in mutation in the expression control region (or expression control sequence), or weaker replacement with an active sequence.
- the expression control region includes, but is not limited to, a promoter, an operator sequence, a sequence encoding a ribosome binding site, and a sequence regulating the termination of transcription and translation.
- the base sequence modification encoding the start codon or 5'-UTR region of the gene transcript encoding the polypeptide is, for example, a base encoding another start codon having a lower polypeptide expression rate than the intrinsic start codon It may be substituted with a sequence, but is not limited thereto.
- the modification of the amino acid sequence or polynucleotide sequence of 4) and 5) above deletes, inserts, non-conservative or conservative substitution of the amino acid sequence of the polypeptide or the polynucleotide sequence encoding the polypeptide to weaken the activity of the polypeptide. Or a combination thereof may result in sequence mutation, or replacement with an amino acid sequence or polynucleotide sequence improved to have weaker activity, or an amino acid sequence or polynucleotide sequence improved to have no activity, but is not limited thereto.
- the expression of a gene may be inhibited or attenuated, but is not limited thereto.
- antisense oligonucleotide eg, antisense RNA
- antisense RNA an antisense oligonucleotide that complementarily binds to the transcript of the gene encoding the polypeptide
- Weintraub, H. et al. Antisense-RNA as a molecular tool. for genetic analysis, Reviews - Trends in Genetics, Vol. 1(1) 1986].
- RTE reverse transcription engineering
- Recombinant microorganisms of the present application are Corynebacterium glutamicum ( Corynebacterium glutamicum ), Corynebacterium crudilactis ), Corynebacterium deserti ( Corynebacterium deserti ), Corynebacterium pisiens ( Corynebacterium deserti ) Corynebacterium efficiens ), Corynebacterium callunae , Corynebacterium stationis , Corynebacterium singulare ), Corynebacterium halotolerans , Corynebacterium halotolerans Corynebacterium striatum ( Corynebacterium striatum ), Corynebacterium ammoniagenes ( Corynebacterium ammoniagenes ), Corynebacterium pollutisoli ( Corynebacterium pollutisoli ), Corynebacterium imitans ( Corynebacterium imitans ), Corynebacter
- the recombinant microorganism of the present application may have increased or improved L-glutamic acid production ability compared to the unmodified microorganism.
- Another aspect of the present application is a method for producing L-glutamic acid, comprising the step of culturing a recombinant microorganism of the genus Corynebacterium for producing L-glutamic acid, comprising a polynucleotide encoding SbtA protein or SbtA protein, in a medium provides
- SbtA protein polynucleotide encoding SbtA protein
- recombinant microorganism are the same as described above.
- the SbtA protein may be derived from cyanobacteria, but is not limited thereto, and this is the same as described above.
- the SbtA protein may have at least 90% identity to SEQ ID NO: 1, but is not limited thereto, and this is the same as described above.
- the recombinant microorganism of the genus Corynebacterium may be Corynebacterium glutamicum, but is not limited thereto, and this is the same as described above.
- the recombinant microorganism may be one in which OdhA is further weakened or odhA is deficient.
- the OdhA may include the amino acid sequence of SEQ ID NO: 29, but is not limited thereto, and this is the same as described above.
- the recombinant microorganism may be the NTG-treated microorganism as the parent strain, but is not limited thereto, and this is the same as described above.
- the term "cultivation” means growing the microorganism in an appropriately controlled environmental condition.
- the culture process of the present application may be made according to a suitable medium and culture conditions known in the art. Such a culture process can be easily adjusted and used by those skilled in the art according to the selected strain. Specifically, the culture may be batch, continuous, and fed-batch, but is not limited thereto.
- the term "medium” refers to a material mixed with nutrients required for culturing the microorganism as a main component, and supplies nutrients and growth factors, including water, which are essential for survival and growth.
- any medium and other culture conditions used for culturing the microorganisms of the present application may be used without any particular limitation as long as they are conventional media used for culturing microorganisms. It can be cultured while controlling temperature, pH, etc. under aerobic conditions in a conventional medium containing compounds, amino acids and/or vitamins.
- the culture medium for the Corynebacterium sp. strain can be found in the literature ["Manual of Methods for General Bacteriology” by the American Society for Bacteriology (Washington D.C., USA, 1981)].
- carbohydrates such as glucose, saccharose, lactose, fructose, sucrose, maltose; sugar alcohols such as mannitol and sorbitol; organic acids such as pyruvic acid, lactic acid, citric acid and the like; Amino acids such as glutamic acid, methionine, lysine, and the like may be included.
- natural organic nutrient sources such as starch hydrolyzate, molasses, blackstrap molasses, rice winter, cassava, sugar cane offal and corn steep liquor can be used, specifically glucose and sterilized pre-treated molasses (i.e., converted to reducing sugar). molasses) may be used, and other suitable carbon sources may be variously used without limitation. These carbon sources may be used alone or in combination of two or more, but is not limited thereto.
- nitrogen source examples include inorganic nitrogen sources such as ammonia, ammonium sulfate, ammonium chloride, ammonium acetate, ammonium phosphate, anmonium carbonate, and ammonium nitrate; Amino acids such as glutamic acid, methionine, glutamine, and organic nitrogen sources such as peptone, NZ-amine, meat extract, yeast extract, malt extract, corn steep liquor, casein hydrolyzate, fish or degradation products thereof, defatted soybean cake or degradation products thereof, etc. can be used These nitrogen sources may be used alone or in combination of two or more, but is not limited thereto.
- inorganic nitrogen sources such as ammonia, ammonium sulfate, ammonium chloride, ammonium acetate, ammonium phosphate, anmonium carbonate, and ammonium nitrate
- Amino acids such as glutamic acid, methionine, glutamine
- organic nitrogen sources such as peptone, NZ-amine, meat extract, yeast extract
- the phosphorus may include potassium monobasic phosphate, dipotassium phosphate, or a sodium-containing salt corresponding thereto.
- potassium monobasic phosphate dipotassium phosphate
- sodium-containing salt corresponding thereto.
- sodium chloride, calcium chloride, iron chloride, magnesium sulfate, iron sulfate, manganese sulfate, calcium carbonate, etc. may be used, and in addition, amino acids, vitamins and/or suitable precursors may be included. These components or precursors may be added to the medium either batchwise or continuously. However, the present invention is not limited thereto.
- compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, sulfuric acid, etc. may be added to the medium in an appropriate manner to adjust the pH of the medium.
- an antifoaming agent such as fatty acid polyglycol ester may be used to suppress bubble formation.
- oxygen or oxygen-containing gas may be injected into the medium, or nitrogen, hydrogen or carbon dioxide gas may be injected without or without gas to maintain anaerobic and microaerobic conditions, and the present invention is limited thereto. it is not
- the temperature of the medium may be 20 °C to 45 °C, specifically 25 °C to 40 °C, but is not limited thereto.
- the incubation period may be continued until a desired production amount of the useful substance is obtained, and specifically, it may be 10 hours to 160 hours, but is not limited thereto.
- the L-glutamic acid produced by the culture may be discharged into the medium or may remain in the cell without being discharged.
- the method for producing L-glutamic acid of the present application may further include the step of preparing a recombinant microorganism of the genus Corynebacterium that produces the L-glutamic acid before the culturing step or preparing a medium for culturing the recombinant microorganism. there is.
- the method for producing L-glutamic acid of the present application may further include the step of recovering L-glutamic acid from the recombinant microorganism or medium after the step of culturing.
- the method of recovering the L-glutamic acid is to collect the desired L-glutamic acid using a suitable method known in the art according to the culture method of the microorganism of the present application, for example, a batch, continuous or fed-batch culture method. collect) may be.
- a suitable method known in the art for example, centrifugation, filtration, anion exchange chromatography, crystallization, HPLC, etc. may be used, and the desired L-glutamic acid may be recovered from the medium or microorganism using a suitable method known in the art.
- the recovery step may include a purification process, and may be performed using a suitable method known in the art.
- the recovered L-glutamic acid may be in a purified form or a microbial fermentation broth containing L-glutamic acid, but is not limited thereto.
- Another aspect of the present application is a recombinant microorganism of the genus Corynebacterium for producing L-glutamic acid, comprising a polynucleotide encoding SbtA protein or SbtA protein; Or a medium culturing the recombinant microorganism; provides a composition for the production of L- glutamic acid comprising.
- SbtA protein polynucleotide encoding SbtA protein
- recombinant microorganism and “medium” are as described above.
- composition of the present application may further include any suitable excipients commonly used in compositions for the production of L-glutamic acid, and these excipients include, for example, preservatives, wetting agents, dispersing agents, suspending agents, buffering agents, stabilizing agents or isotonic agents. and the like, but is not limited thereto.
- a plasmid (pDCM2, FIG. 1, SEQ ID NO: 32) for the insertion and replacement of genes in the Corynebacterium chromosome was designed, and the plasmid was synthesized using the gene-synthesis service of Binix Co., Ltd.
- a plasmid was designed to include a restriction enzyme that is easy to use for cloning by referring to the generally known sacB system related paper [Gene, 145 (1994) 69-73].
- the thus synthesized pDCM2 plasmid has the following characteristics.
- Cyanobacteria specifically, Synechocystis sp.
- sbtA and bicA genes encoding the bicarbonate (HCO 3 - ) transporter derived from PCC6803, Synechocystis sp.
- HCO 3 - bicarbonate transporter
- sbtA (SEQ ID NO: 3) from Synechocystis genus PCC6803 was codon-optimized for Corynebacterium glutamicum (SEQ ID NO: 2) and PCC6803 derived bicA (SEQ ID NO: 6) was synthesized and codon-optimized for Corynebacterium glutamicum (SEQ ID NO: 5).
- pDCM2 vector was used for the insertion of the two genes, and the CJ7 synthesis promoter (Korean Patent Registration No. 10-0620092 and International Patent Publication No. 2006-065095) was used as the expression promoter.
- BBD29_01410 (hereinafter referred to as CglE0286) and BBD29_00440 ( Hereafter, the pDCM2- ⁇ CglE0286::CJ7-sbtA vector and the pDCM2- ⁇ CglE0085::CJ7-bicA vector were constructed using the CglE0085) location.
- CglE0286 in which homologous recombination occurs using primer sets of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10 using Corynebacterium glutamicum ATCC13869 chromosomal DNA as a template Gene fragments of the upstream region and the downstream region were obtained through PCR.
- Solg TM Pfu-X DNA polymerase was used as the polymerase, and PCR amplification conditions were repeated 30 times of denaturation at 95°C for 5 minutes, denaturation at 95°C for 30 seconds, annealing at 58°C for 30 seconds, and polymerization at 72°C for 60 seconds. , the polymerization was carried out at 72 °C for 5 minutes.
- the amplified CglE0286 upstream and downstream regions, and the vector pDCM2 for chromosomal transformation digested with EcoRI and SalI restriction enzymes were prepared by Gibson assembly (DG Gibson et al., NATURE METHODS, VOL.6 NO.5, MAY 2009, NEBuilder HiFi DNA).
- a recombinant plasmid was obtained by cloning using the Assembly Master Mix) method, and was named pDCM2- ⁇ CglE0286. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment with the calculated mole number and then storing at 50° C. for 1 hour.
- PCR was performed using the synthesized CJ7-sbtA of SEQ ID NO: 11 as a template and primers of SEQ ID NO: 12 and SEQ ID NO: 13, and the CJ7-sbtA gene fragment was obtained through PCR.
- Solg TM Pfu-X DNA polymerase was used as the polymerase, and PCR amplification conditions were repeated 30 times of denaturation at 95°C for 5 minutes, denaturation at 95°C for 30 seconds, annealing at 58°C for 30 seconds, and polymerization at 72°C for 60 seconds. , the polymerization was carried out at 72 °C for 5 minutes.
- a recombinant plasmid was obtained by cloning the amplified CJ7-sbtA and the vector pDCM2- ⁇ CglE0286 for chromosomal transformation cut with ScaI restriction enzyme using the Gibson assembly method, and it was named pDCM2- ⁇ CglE0286::CJ7-sbtA. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment with the calculated mole number and then storing at 50° C. for 1 hour.
- CglE0085 upstream region and downstream in which chromosomal homologous recombination occurs using primer sets of SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16 and SEQ ID NO: 17 using Corynebacterium glutamicum ATCC13869 chromosomal DNA as a template Local gene fragments were obtained through PCR.
- Solg TM Pfu-X DNA polymerase was used as the polymerase, and PCR amplification conditions were repeated 30 times of denaturation at 95°C for 5 minutes, denaturation at 95°C for 30 seconds, annealing at 58°C for 30 seconds, and polymerization at 72°C for 60 seconds. , the polymerization was carried out at 72 °C for 5 minutes.
- a recombinant plasmid was obtained by cloning the amplified CglE0085 upstream and downstream regions, and the vector pDCM2 for chromosomal transformation cut with EcoRI and SalI restriction enzymes using the Gibson assembly method, and was named pDCM2- ⁇ CglE0085. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment with the calculated mole number and then storing at 50° C. for 1 hour.
- PCR was performed using the synthesized CJ7-bicA of SEQ ID NO: 18 as a template and primers of SEQ ID NO: 12 and SEQ ID NO: 13 to obtain a CJ7-bicA gene fragment.
- Solg TM Pfu-X DNA polymerase was used as the polymerase, and PCR amplification conditions were repeated 30 times of denaturation at 95°C for 5 minutes, denaturation at 95°C for 30 seconds, annealing at 58°C for 30 seconds, and polymerization at 72°C for 60 seconds. , the polymerization was carried out at 72 °C for 5 minutes.
- Recombinant plasmid was obtained by cloning the amplified CJ7-bicA and the vector pDCM2- ⁇ CglE0085 for chromosomal transformation cut with ScaI restriction enzyme using the Gibson assembly method, and it was named pDCM2- ⁇ CglE0085::CJ7-bicA. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment with the calculated mole number and then storing at 50° C. for 1 hour.
- Example 3 Wild-type Corynebacterium glutamicum-derived L-glutamic acid production strain production and bicarbonate transporter introduction strain production
- Example 3-1 Preparation of Corynebacterium glutamicum strain having L-glutamic acid-producing ability derived from wild-type Corynebacterium glutamicum
- Corynebacterium glutamicum ATCC13869 odhA based on the prior literature (Appl Environ Microbiol. 2007 Feb; 73(4): 1308-19. Epub 2006 Dec 8.) to produce a strain having L-glutamic acid-producing ability derived from ATCC13869 A strain of Corynebacterium glutamicum ATCC13869 ⁇ odhA in which the gene was deleted was prepared.
- the upstream region and downstream region of the odhA gene using the primer sets of SEQ ID NO: 19 and SEQ ID NO: 20, SEQ ID NO: 21 and SEQ ID NO: 22 using Corynebacterium glutamicum ATCC13869 chromosomal DNA as a template was obtained through PCR.
- Solg TM Pfu-X DNA polymerase was used as the polymerase, and PCR amplification conditions were repeated 30 times of denaturation at 95°C for 5 minutes, denaturation at 95°C for 30 seconds, annealing at 58°C for 30 seconds, and polymerization at 72°C for 60 seconds. , the polymerization was carried out at 72 °C for 5 minutes.
- a recombinant plasmid was obtained by cloning the amplified odhA upstream and downstream regions, and the vector pDCM2 for chromosomal transformation cut with SmaI restriction enzyme using the Gibson assembly method, and was named pDCM2- ⁇ odhA. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment with the calculated mole number and then storing at 50° C. for 1 hour.
- the prepared pDCM2- ⁇ odhA vector was transformed into a Corynebacterium glutamicum ATCC13869 strain by electroporation, and then a strain in which the odhA gene was deleted was obtained through a secondary crossover process.
- the gene deletion was confirmed through PCR and genome sequencing using SEQ ID NO: 23 and SEQ ID NO: 24, and the prepared strain was named ATCC13869 ⁇ odhA.
- Example 3-2 Preparation of strains having L-glutamic acid-producing ability derived from wild-type Corynebacterium glutamicum introduced with a bicarbonate transporter
- the genetic manipulation was confirmed through PCR and genome sequencing using SEQ ID NO: 25 and SEQ ID NO: 26 that can amplify the external regions of the upstream region and the downstream region of the homologous recombination into which the CJ7-sbtA gene was introduced, respectively. was named CA02-1474.
- the pDCM2- ⁇ CglE0085::CJ7-bicA vector of Example 2 was transformed into the Corynebacterium glutamicum ATCC13869 ⁇ odhA strain by electroporation, and then CJ7 at the CglE0085 position on the chromosome through a secondary crossover process. A strain into which the -bicA gene was inserted was obtained.
- the genetic manipulation was confirmed through PCR and genome sequencing using SEQ ID NO: 27 and SEQ ID NO: 28, which can amplify the external regions of the upstream region and the downstream region of the homologous recombination into which the CJ7-bicA gene was introduced, respectively. was named CA02-1475.
- CA02-1474 strain and CA02-1475 strain prepared above were cultured using the ATCC13869 ⁇ odhA strain as a control to check the L-glutamic acid production ability as follows.
- the strains were inoculated on a plate medium consisting of a seed medium and incubated at 30° C. for 20 hours. Then, the strain was inoculated with 1 platinum in a 250 ml corner-baffle flask containing 25 ml of the following production medium, and cultured with shaking at 30° C. for 40 hours at 200 rpm. After completion of the culture, the production of L-glutamic acid was measured using high performance liquid chromatography (HPLC), and the measurement results are shown in Table 4 below.
- HPLC high performance liquid chromatography
- CA02-1474 was deposited with the Korea Microorganism Conservation Center, a trustee institution under the Budapest Treaty on July 28, 2020, and was given an accession number KCCM12775P.
- Example 4 Bicarbonate transporter-introduced N-methyl-N'-nitro-N-nitrosoguanidine (N-Methyl-N'-nitro-N-nitrosoguanidine, NTG) mutant-derived L-glutamic acid-producing ability Corynebacterium glutamicum strain production
- the KFCC11074 strain known as the L-glutamic acid-producing NTG mutant strain in order to confirm whether the gene exhibits the same effect in the NTG mutant Corynebacterium genus-derived strain with increased L-glutamic acid production ability.
- the gene was introduced into (Korea Patent Registration No. 10-0292299).
- the strains were inoculated on a plate medium consisting of a seed medium and incubated at 30° C. for 20 hours. Then, the strain was inoculated with 1 platinum in a 250 ml corner-baffle flask containing 25 ml of the following production medium, and cultured with shaking at 30° C. for 40 hours at 200 rpm. After completion of the culture, the production of L-glutamic acid was measured using high performance liquid chromatography (HPLC), and the measurement results are shown in Table 5 below.
- HPLC high performance liquid chromatography
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
서열번호 | 명칭 | 서열 |
7 | CglE0286_up_F | aacgacggccagtgaattcCGGACGTTTACGCTGAT |
8 | CglE0286_up_R | AGTACTaaaccggaagggccTGTAAAGGCC |
9 | CglE0286_down_F | ccttccggtttAGTACTaaacaggaagagccCCTTTA |
10 | CglE0286_down_R | tgcatgcctgcaggtcgacCGCATGTGGTGGCAAAA |
12 | CJ7-sbtA_F | ggcccttccggtttagt |
13 | CJ7-sbtA_R | GGCTCTTCCTGTTTAGT |
14 | CglE0085_up_F | aacgacggccagtgaattcGCTCGAATGCCTGACTGACA |
15 | CglE0085_up_R | gtttAGTACTaaaccggaagggccAAAGGACGACTTCACGGTTA |
16 | CglE0085_down_F | ccggtttAGTACTaaacaggaagagccATTGAGGATGCGAAACTGT |
17 | CglE0085_down_R | tgcatgcctgcaggtcgacGTAATCGAATCACCGGCCAG |
서열번호 | 명칭 | 서열 |
19 | odhA_up_F | TGAATTCGAGCTCGGTACCCTTGAACGGAATTGGGTGG |
20 | odhA_up_R | CCCAGGTGGCATCGGTACCTTCACCCAGCGCCACGCAG |
21 | odhA_down_F | CGCTGGGTGAAGGTACCGATGCCACCTGGGTTGGTCAAG |
22 | odhA_down_R | GTCGACTCTAGAGGATCCCCGGACAAGGAATGGAGAGA |
23 | odhA_del_F | CTTACCGTTGTTGCCCTT |
24 | odhA_del_R | CTCCTTCACCCACATCATT |
서열번호 | 명칭 | 서열 |
25 | CJ7-sbtA_confirm_F | CAAGCAGCAAGTGCCACAC |
26 | CJ7-sbtA_confirm_R | CCAACTGCTCCGACGAAG |
27 | CJ7-bicA_confirm_F | ATTCCCAAAGGTGCCAGC |
28 | CJ7-bicA_confirm_R | CAGTGCGCAAAAGGCCTC |
균주명 | L-글루탐산 농도(g/L) | L-글루탐산 농도 증가율(%) |
ATCC13869△odhA | 1.9 | - |
CA02-1474 | 2.9 | 52.6% |
CA02-1475 | 2.1 | 10.5% |
균주명 | L-글루탐산 농도(g/L) | L-글루탐산 농도 증가율(%) |
KFCC11074 | 6.9 | - |
CA02-1476 | 9.3 | 34.8% |
Claims (11)
- SbtA 단백질 또는 SbtA 단백질을 코딩하는 폴리뉴클레오티드를 포함하는, L-글루탐산(L-glutamic acid)을 생산하는 코리네박테리움 속(the genus of Corynebacterium) 재조합 미생물.
- 제1항에 있어서, 상기 단백질은 시아노박테리아(Cyanobacteria) 유래인, 재조합 미생물.
- 제1항에 있어서, 상기 단백질은 서열번호 1 또는 이와 90% 이상의 서열 동일성을 갖는 아미노산 서열을 포함하는, 재조합 미생물.
- 제1항에 있어서, 상기 코리네박테리움 속 미생물은 코리네박테리움 글루타미쿰(Corynebacterium glutamicum)인, 재조합 미생물.
- 제1항에 있어서, 상기 재조합 미생물은 OdhA 단백질이 추가로 약화된, 재조합 미생물.
- SbtA 단백질 또는 SbtA 단백질을 코딩하는 폴리뉴클레오티드를 포함하는, L-글루탐산을 생산하는 코리네박테리움 속 재조합 미생물을 배지에서 배양하는 단계를 포함하는, L-글루탐산 제조방법.
- 제6항에 있어서, 상기 단백질은 시아노박테리아 유래인, 제조방법.
- 제6항에 있어서, 상기 단백질은 서열번호 1 또는 이와 90% 이상의 서열 동일성을 갖는 아미노산 서열을 포함하는, 제조방법.
- 제6항에 있어서, 상기 코리네박테리움 속 재조합 미생물은 코리네박테리움 글루타미쿰인, 제조방법.
- 제6항에 있어서, 상기 제조방법은 상기 재조합 미생물 또는 배지로부터 L-글루탐산을 회수하는 단계를 추가적으로 포함하는, 제조방법.
- 제6항에 있어서, 상기 재조합 미생물은 OdhA 단백질이 추가로 약화된, 제조방법.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112023004335A BR112023004335A2 (pt) | 2020-09-09 | 2021-06-30 | Microrganismo recombinante para produzir ácido l-glutâmico e um método para produzir ácido l-glutâmico usando o mesmo |
CN202180070938.9A CN116323951A (zh) | 2020-09-09 | 2021-06-30 | 生产l-谷氨酸的重组微生物及利用其生产l-谷氨酸的方法 |
AU2021341221A AU2021341221A1 (en) | 2020-09-09 | 2021-06-30 | A recombinant microorganism for producing L-glutamic acid and a method for producing L-glutamic acid using the same |
MX2023002783A MX2023002783A (es) | 2020-09-09 | 2021-06-30 | Un microorganismo recombinante para producir acido l-glutamico y un metodo para producir acido l-glutamico utilizando el mismo. |
US18/025,050 US20230323413A1 (en) | 2020-09-09 | 2021-06-30 | A recombinant microorganism for producing l-glutamic acid and a method for producing l-glutamic acid using the same |
EP21866964.6A EP4198132A4 (en) | 2020-09-09 | 2021-06-30 | RECOMBINANT MICROORGANISM FOR THE PRODUCTION OF L-GLUTAMIC ACID AND METHOD FOR THE PRODUCTION OF L-GLUTAMIC ACID THEREOF |
JP2023514716A JP2023540315A (ja) | 2020-09-09 | 2021-06-30 | L-グルタミン酸生産組換え微生物及びそれを用いたl-グルタミン酸製造方法 |
CA3191344A CA3191344A1 (en) | 2020-09-09 | 2021-06-30 | A recombinant microorganism for producing l-glutamic acid and a method for producing l-glutamic acid using the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200115570 | 2020-09-09 | ||
KR10-2020-0115570 | 2020-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022055094A1 true WO2022055094A1 (ko) | 2022-03-17 |
Family
ID=80631917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/008262 WO2022055094A1 (ko) | 2020-09-09 | 2021-06-30 | L-글루탐산 생산 재조합 미생물 및 이를 이용한 l-글루탐산의 제조방법 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230323413A1 (ko) |
EP (1) | EP4198132A4 (ko) |
JP (1) | JP2023540315A (ko) |
CN (1) | CN116323951A (ko) |
AR (1) | AR123450A1 (ko) |
AU (1) | AU2021341221A1 (ko) |
BR (1) | BR112023004335A2 (ko) |
CA (1) | CA3191344A1 (ko) |
MX (1) | MX2023002783A (ko) |
WO (1) | WO2022055094A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024014700A1 (ko) * | 2022-07-11 | 2024-01-18 | 대상 주식회사 | L-글루탐산을 생산하는 코리네박테리움 속 변이 미생물 및 이를 이용한 l-글루탐산의 생산 방법 |
WO2024096219A1 (ko) * | 2022-10-31 | 2024-05-10 | 대상 주식회사 | L-글루탐산을 생산하는 코리네박테리움 속 변이 미생물 및 이를 이용한 l-글루탐산의 생산 방법 |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3220929A (en) | 1964-02-10 | 1965-11-30 | Kyowa Hakko Kogyo Kk | Microbiological production of amino acid by reductive amination |
KR100292299B1 (ko) | 1999-03-22 | 2001-06-01 | 손경식 | 글루탐산 생산 미생물 및 이를 이용한 글루탐산 생산방법 |
US6682912B2 (en) | 1998-03-18 | 2004-01-27 | Ajinomoto Co., Inc. | L-glutamic acid-producing bacterium and method for producing L-glutamic acid |
US20040024182A1 (en) * | 2001-07-03 | 2004-02-05 | Henry Yue | Gtp-binding proteins |
WO2006065095A1 (en) | 2004-12-16 | 2006-06-22 | Cj Corporation | Novel promoter nucleic acid derived from corynebacterium genus bacteria, expression cassette comprising the promoter and vector comprising the cassette, host cell comprising the vector and method for expressing a gene using the cell |
KR20080034334A (ko) * | 2006-10-16 | 2008-04-21 | 씨제이제일제당 (주) | 고농도의 글루탐산을 생산하는 미생물 및 이를 이용한글루탐산의 제조 방법 |
KR20100017581A (ko) * | 2004-12-28 | 2010-02-16 | 아지노모토 가부시키가이샤 | L-글루탐산 생산 미생물 및 l-글루탐산의 제조방법 |
US8030036B2 (en) | 2003-07-29 | 2011-10-04 | Ajinomoto Co., Inc. | Method for producing L-lysine or L-threonine |
WO2012040361A2 (en) * | 2010-09-21 | 2012-03-29 | Joule Unlimited Technologies, Inc. | Methods and compositions for limiting viability of a modified host cell outside of designated process conditions |
US9109242B2 (en) | 2006-09-15 | 2015-08-18 | Cj Cheiljedang Corporation | Corynebacteria having enhanced L-lysine productivity and a method of producing L-lysine using the same |
KR20160145827A (ko) * | 2014-04-30 | 2016-12-20 | 에보닉 데구사 게엠베하 | 호알칼리성 박테리아를 사용하는 l-아미노산 생산 방법 |
US10273491B2 (en) | 2015-01-29 | 2019-04-30 | Cj Cheiljedang Corporation | Promoter and uses thereof |
US10584338B2 (en) | 2016-08-31 | 2020-03-10 | Cj Cheiljedang Corporation | Promoter and use thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101315068B1 (ko) * | 2011-02-07 | 2013-10-08 | 한국생명공학연구원 | 시네코시스티스 속 PCC6803 유래 SbtA 유전자 및 이의 용도 |
-
2021
- 2021-06-30 JP JP2023514716A patent/JP2023540315A/ja active Pending
- 2021-06-30 CA CA3191344A patent/CA3191344A1/en active Pending
- 2021-06-30 US US18/025,050 patent/US20230323413A1/en active Pending
- 2021-06-30 CN CN202180070938.9A patent/CN116323951A/zh active Pending
- 2021-06-30 BR BR112023004335A patent/BR112023004335A2/pt unknown
- 2021-06-30 WO PCT/KR2021/008262 patent/WO2022055094A1/ko unknown
- 2021-06-30 MX MX2023002783A patent/MX2023002783A/es unknown
- 2021-06-30 AU AU2021341221A patent/AU2021341221A1/en active Pending
- 2021-06-30 EP EP21866964.6A patent/EP4198132A4/en active Pending
- 2021-09-08 AR ARP210102489A patent/AR123450A1/es unknown
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3220929A (en) | 1964-02-10 | 1965-11-30 | Kyowa Hakko Kogyo Kk | Microbiological production of amino acid by reductive amination |
US6682912B2 (en) | 1998-03-18 | 2004-01-27 | Ajinomoto Co., Inc. | L-glutamic acid-producing bacterium and method for producing L-glutamic acid |
KR100292299B1 (ko) | 1999-03-22 | 2001-06-01 | 손경식 | 글루탐산 생산 미생물 및 이를 이용한 글루탐산 생산방법 |
US20040024182A1 (en) * | 2001-07-03 | 2004-02-05 | Henry Yue | Gtp-binding proteins |
US8030036B2 (en) | 2003-07-29 | 2011-10-04 | Ajinomoto Co., Inc. | Method for producing L-lysine or L-threonine |
KR100620092B1 (ko) | 2004-12-16 | 2006-09-08 | 씨제이 주식회사 | 코리네박테리움 속 세포로부터 유래된 신규한 프로모터서열, 그를 포함하는 발현 카세트 및 벡터, 상기 벡터를포함하는 숙주 세포 및 그를 이용하여 유전자를 발현하는방법 |
US7662943B2 (en) | 2004-12-16 | 2010-02-16 | Cj Cheiljedang Corporation | Promoter sequences from Corynebacterium ammoniagenes |
WO2006065095A1 (en) | 2004-12-16 | 2006-06-22 | Cj Corporation | Novel promoter nucleic acid derived from corynebacterium genus bacteria, expression cassette comprising the promoter and vector comprising the cassette, host cell comprising the vector and method for expressing a gene using the cell |
KR20100017581A (ko) * | 2004-12-28 | 2010-02-16 | 아지노모토 가부시키가이샤 | L-글루탐산 생산 미생물 및 l-글루탐산의 제조방법 |
US9109242B2 (en) | 2006-09-15 | 2015-08-18 | Cj Cheiljedang Corporation | Corynebacteria having enhanced L-lysine productivity and a method of producing L-lysine using the same |
KR20080034334A (ko) * | 2006-10-16 | 2008-04-21 | 씨제이제일제당 (주) | 고농도의 글루탐산을 생산하는 미생물 및 이를 이용한글루탐산의 제조 방법 |
WO2012040361A2 (en) * | 2010-09-21 | 2012-03-29 | Joule Unlimited Technologies, Inc. | Methods and compositions for limiting viability of a modified host cell outside of designated process conditions |
KR20160145827A (ko) * | 2014-04-30 | 2016-12-20 | 에보닉 데구사 게엠베하 | 호알칼리성 박테리아를 사용하는 l-아미노산 생산 방법 |
US10273491B2 (en) | 2015-01-29 | 2019-04-30 | Cj Cheiljedang Corporation | Promoter and uses thereof |
US10584338B2 (en) | 2016-08-31 | 2020-03-10 | Cj Cheiljedang Corporation | Promoter and use thereof |
Non-Patent Citations (21)
Title |
---|
"Atlas Of Protein Sequence And Structure,", 1979, NATIONAL BIOMEDICAL RESEARCH FOUNDATION, pages: 353 - 358 |
"GenBank", Database accession no. WP_060564343.1 |
"Manual of Methods for General Bacteriology", 1981, AMERICAN SOCIETY FOR BACTERIOLOGY |
APPL ENVIRON MICROBIOL, vol. 73, no. 4, February 2007 (2007-02-01), pages 1308 - 19 |
ATSCHUL, S. F. ET AL., J MOLEC BIOL, vol. 215, 1990, pages 403 |
CARILLO ET AL., SIAM J APPLIED MATH, vol. 48, 1988, pages 1073 |
DEVEREUX, J. ET AL., NUCLEIC ACIDS RESEARCH, vol. 12, 1984, pages 387 |
DG GIBSON ET AL.: "NEBuilder HiFi DNA Assembly Master Mix", NATURE METHODS, vol. 6, no. 5, May 2009 (2009-05-01) |
GENE, vol. 145, 1994, pages 69 - 73 |
GRIBSKOV ET AL., NUCL. ACIDS RES, vol. 14, 1986, pages 6745 |
J. SAMBROOK ET AL.: "Molecular Cloning, A Laboratory Manual,", 1989, COLD SPRING HARBOR LABORATORY PRESS |
NAKASHIMA N ET AL.: "Bacterial cellular engineering by genome editing and gene silencing", INT J MOL SCI, vol. 15, no. 2, 2014, pages 2773 - 2793, XP055376889, DOI: 10.3390/ijms15022773 |
NEEDLEMAN ET AL., J MOL BIOL., vol. 48, 1970, pages 443 |
NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443 - 453 |
PEARSON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 50-51, 1988, pages 2444 - 8 |
RICE ET AL., TRENDS GENET., vol. 16, 2000, pages 276 - 277 |
SAMBROOK ET AL., MOLECULAR CLONING, 2012 |
See also references of EP4198132A4 |
SITNICKA ET AL.: "Functional Analysis of Genes", ADVANCES IN CELL BIOLOGY, vol. 2, 2010, pages 1 - 16 |
SMITHWATERMAN, ADV. APPL. MATH, vol. 2, 1981, pages 482 |
WEINTRAUB, H. ET AL., ANTISENSE-RNA AS A GENETICS,, vol. 1, no. 1, 1986 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024014700A1 (ko) * | 2022-07-11 | 2024-01-18 | 대상 주식회사 | L-글루탐산을 생산하는 코리네박테리움 속 변이 미생물 및 이를 이용한 l-글루탐산의 생산 방법 |
WO2024096219A1 (ko) * | 2022-10-31 | 2024-05-10 | 대상 주식회사 | L-글루탐산을 생산하는 코리네박테리움 속 변이 미생물 및 이를 이용한 l-글루탐산의 생산 방법 |
Also Published As
Publication number | Publication date |
---|---|
CA3191344A1 (en) | 2022-03-17 |
AU2021341221A1 (en) | 2023-04-06 |
EP4198132A1 (en) | 2023-06-21 |
JP2023540315A (ja) | 2023-09-22 |
TW202210629A (zh) | 2022-03-16 |
EP4198132A4 (en) | 2024-04-24 |
CN116323951A (zh) | 2023-06-23 |
BR112023004335A2 (pt) | 2023-04-04 |
AR123450A1 (es) | 2022-11-30 |
MX2023002783A (es) | 2023-03-15 |
US20230323413A1 (en) | 2023-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022163934A1 (ko) | 신규한 d-알라닌-d-알라닌 리가아제 a 변이체 및 이를 이용한 l-글루탐산 생산 방법 | |
WO2022055094A1 (ko) | L-글루탐산 생산 재조합 미생물 및 이를 이용한 l-글루탐산의 제조방법 | |
WO2022231368A1 (ko) | 신규한 글루타메이트 합성 효소 서브 유니트 알파 변이체 및 이를 이용한 l-글루탐산 생산 방법 | |
WO2022163935A1 (ko) | 신규한 글루코사민-6-포스페이트 디아미나제 변이체 및 이를 이용한 l-글루탐산 생산 방법 | |
WO2022191630A1 (ko) | 신규한 시트레이트 신타아제 변이체 및 이를 이용한 l-발린 생산 방법 | |
WO2022154191A1 (ko) | 신규한 2,5-다이케토-d-글루콘산 리덕타제 변이체 및 이를 이용한 xmp 또는 gmp 생산 방법 | |
WO2022154190A1 (ko) | 신규한 포스포노아세테이트 하이드롤라제 변이체 및 이를 이용한 xmp 또는 gmp 생산 방법 | |
WO2022154181A1 (ko) | 신규한 1,4-알파-글루칸-분지 효소 변이체 및 이를 이용한 imp 생산 방법 | |
WO2022154177A1 (ko) | 신규한 3d-(3,5/4)-트리하이드록시사이클로헥세인-1,2-다이온 아실하이드롤라아제 변이체 및 이를 이용한 imp 생산 방법 | |
WO2022163923A1 (ko) | 신규한 atp 포스포리보실트랜스퍼라제 변이체 및 이를 이용한 l-발린 생산 방법 | |
WO2022163920A1 (ko) | 신규한 시스테인 설피네이트 디설피나제 변이체 및 이를 이용한 l-발린 생산 방법 | |
WO2022163904A1 (ko) | 신규한 단백질 변이체 및 이를 이용한 l-라이신 생산 방법 | |
WO2022005022A1 (ko) | L-이소류신 생산능이 강화된 미생물 및 이를 이용한 l-이소류신 생산방법 | |
WO2022163936A1 (ko) | 신규한 엑시뉴클레아제 abc 서브유닛 a 변이체 및 이를 이용한 l-글루탐산 생산 방법 | |
WO2022163938A1 (ko) | 신규한 리보뉴클레아제 p 변이체 및 이를 이용한 l-글루탐산 생산 방법 | |
WO2022163937A1 (ko) | 신규한 abc 트랜스포터 atp-결합 단백질 변이체 및 이를 이용한 l-글루탐산 생산 방법 | |
WO2022163940A1 (ko) | 신규한 갈락토사이드 o-아세틸트랜스퍼라제 변이체 및 이를 이용한 l-글루탐산 생산 방법 | |
WO2022163933A1 (ko) | 신규한 abc 트랜스포터 atp-결합 단백질 변이체 및 이를 이용한 l-글루탐산 생산 방법 | |
WO2022163941A1 (ko) | 신규한 스퍼미딘 신타아제 변이체 및 이를 이용한 l-글루탐산 생산 방법 | |
WO2022163939A1 (ko) | 신규한 mfs 트랜스포터 변이체 및 이를 이용한 l-글루탐산 생산 방법 | |
WO2022154189A1 (ko) | 신규한 피토엔 신타제 변이체 및 이를 이용한 xmp 또는 gmp 생산 방법 | |
WO2022154188A1 (ko) | 신규한 폴리케타이드 신타제 변이체 및 이를 이용한 xmp 또는 gmp 생산 방법 | |
WO2022154179A1 (ko) | 신규한 d-알라닌--d-알라닌 리가아제 변이체 및 이를 이용한 imp 생산 방법 | |
WO2022163929A1 (ko) | 신규한 펩티딜-디펩티다제 변이체 및 이를 이용한 xmp 또는 gmp 생산 방법 | |
WO2022163924A1 (ko) | 신규한 5,10-메틸렌테트라하이드로폴레이트 리덕타제 변이체 및 이를 이용한 l-발린 생산 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21866964 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3191344 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2023514716 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023004335 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2021866964 Country of ref document: EP Effective date: 20230317 |
|
ENP | Entry into the national phase |
Ref document number: 112023004335 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230308 |
|
ENP | Entry into the national phase |
Ref document number: 2021341221 Country of ref document: AU Date of ref document: 20210630 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |